MARKET COMPOSITE
Market TodayThemes and Stocks SummaryThematic Stock SearchDaily Refresh Schedule
PYPD - Polypid Ltd
$6.94
0.01(0.14%)6:00:00 PM 11/26/2021
Stock Chart
leak data

Short Volume Ratio = Short Volume / All Volume. Source of Short Volume data comes from 

Finra

Moving Average Convergence/Divergence oscillator (MACD) is one of the simplest and most effective momentum indicators available.

Relative Strength Index (RSI) is a momentum oscillator that measures the speed and change of price movements. RSI oscillates between zero and 100. According to Wilder, RSI is considered overbought when above 70 and oversold when below 30.

No summary
Related Topics
leak data

Related Topics

Stock news

    11/18/2021PYPD
    PolyPid Announces 500th Patient Enrolled in SHIELD I Phase 3 Clinical Trial of D-PLEX₁₀₀ in Abdominal Surgery

    Company Continues to Expect that the Last Patient Will be Enrolled in the Second Quarter of 2022, Followed by Top-Line Results Two Months ThereafterPETAH TIKVA, Israel, Nov. 18, 2021 (GLOBE NEWSWIRE) -- PolyPid Ltd. (Nasdaq: PYPD) (“PolyPid” or the “Company”), a phase 3 biopharmaceutical company focused on developing targeted, locally administered, and prolonged-release therapeutics to improve surgical outcomes, announced today that the 500th patient has been enrolled into its ongoing Phase 3 SH

    11/16/2021PYPD
    Does PolyPid Ltd. (PYPD) Have the Potential to Rally 166% as Wall Street Analysts Expect?

    The average of price targets set by Wall Street analysts indicates a potential upside of 165.8% in PolyPid Ltd. (PYPD). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.

    11/16/2021PYPD
    PolyPid Appoints New Oncology Advisory Board Member

    Company is Scheduled to Conduct Pre-IND Meeting with the U.S. FDA Later This Month and Potentially Initiate Phase 1/2 Clinical Trial of OncoPLEX for Brain Tumors in 2022PETAH TIKVA, Israel, Nov. 16, 2021 (GLOBE NEWSWIRE) -- PolyPid Ltd. (Nasdaq: PYPD) (“PolyPid” or the “Company”), a phase 3 biopharmaceutical company focused on developing targeted, locally administered, and prolonged-release therapeutics using its proprietary PLEX technology, today announced the appointment of Frederick Lang, M.D

    11/10/2021PYPD
    PolyPid Ltd. Reports Third Quarter 2021 Financial Results and Provides Corporate Update

    Recruitment Progressing as Planned with Approximately 480 Patients Enrolled in Phase 3 SHIELD I Trial of D-PLEX100 in Abdominal Surgery Following FDA Agreement that a Single Pivotal Phase 3 Study is Sufficient for Potential Approval of D-PLEX100 for the Prevention of Surgical Site Infections in Colorectal Surgery, Company Intends to Target Higher End of Patient Enrollment Range in SHIELD I to Leverage Key Clinical, Commercial and Financial Benefits Company’s Cash Runway Extends to Year-End 2022,

    11/1/2021PYPD
    PolyPid to Report Third Quarter 2021 Financial Results and Operational Highlights on November 10, 2021

    PETAH TIKVA, Israel, Nov. 01, 2021 (GLOBE NEWSWIRE) -- PolyPid Ltd. (Nasdaq: PYPD) (“PolyPid” or the “Company”), a phase 3 biopharmaceutical company focused on developing targeted, locally administered, and prolonged-release therapeutics using its proprietary PLEX technology, today announced that it will report its third quarter 2021 financial results and operational highlights before the open of the U.S. stock markets on Wednesday, November 10, 2021. The Company will host a conference call and

    09/27/2021PYPD
    We're Keeping An Eye On PolyPid's (NASDAQ:PYPD) Cash Burn Rate

    There's no doubt that money can be made by owning shares of unprofitable businesses. For example, although Amazon.com...

    09/20/2021PYPD
    PolyPid to Present at Upcoming Cantor Fitzgerald Global Healthcare Conference

    PETAH TIKVA, Israel, Sept. 20, 2021 (GLOBE NEWSWIRE) -- PolyPid Ltd. (Nasdaq: PYPD), a phase 3 biopharmaceutical company focused on developing targeted, locally administered, and prolonged-release therapeutics using its proprietary PLEX technology, today announced its participation in the Cantor Fitzgerald Virtual Global Healthcare Conference on September 29 at 02:00 pm EDT. In her presentation, Dikla Czaczkes Akselbrad, Polypid’s EVP and CFO will provide corporate highlights and discuss recent

    09/13/2021PYPD
    PolyPid Shares Preclinical Data Of OncoPLEX Program For Brain Tumor

    PolyPid Ltd (NASDAQ: PYPD) has announced preclinical data in two key Glioblastoma Multiform (GBM) animal models of its OncoPLEX intra-tumoral cancer therapy program. OncoPLEX is designed to provide controlled local exposure to docetaxel, one of the most widely used chemotherapy agents. OncoPLEX induced strong inhibition of tumor growth and recurrence in a partially resected human glioblastoma subcutaneous mouse model. A single local OncoPLEX application induced 98% tumor growth inhibition (day 4